A Pilot Trial to Evaluate the Effects of Dextromethorphan in Patients Suffering From Cancer-Related Fatigue
- Assess the effects of dextromethorphan hydrobromide in patients with cancer-related
- Correlate the changes in cancer-related fatigue with the levels of plasma homocysteine
versus red blood cell folate.
OUTLINE: This is a multicenter, open-label, pilot study.
Patients receive oral dextromethorphan hydrobromide 3 times a day on days 1-7. Treatment
repeats weekly for up to 3 weeks in the absence of disease progression or unacceptable
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Supportive Care
Susan Goodin, PharmD, FCCP, BCOP
Cancer Institute of New Jersey
United States: Federal Government
|Cancer Institute of New Jersey at Hamilton||Hamilton, New Jersey 08690|
|Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School||New Brunswick, New Jersey 08903|